ZLD1039 is another potent and selective SAM- EZH2 inhibitor, which has not been so widely investigated [45,46] but has been shown to have concentration-dependent inhibition of PRC2 enzymatic activity against EZH2 in melanoma cells and breast cancer [47,48]. Here, EZH2 is linked to breast carcinoma.